We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ECVT:NYSEEcovyst Inc. Analysis

Data as of 2026-06-17 - not real-time

$13.04

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Ecovyst’s stock is currently trading just below its 20‑day and 50‑day simple moving averages, signaling a modest short‑term weakness. The 14‑day RSI sits in the mid‑40s, reflecting neutral momentum rather than oversold conditions. A bearish MACD crossover, with the line under the signal, adds technical pressure. The price is hovering just above a well‑defined support zone near $12.5, while resistance sits above $14.2. Volume trends are declining, and the 30‑day volatility exceeds 30%, indicating a choppy trading environment. Beta below one points to lower sensitivity to broad market swings, tempering systematic risk.
On the valuation side, the trailing PE is exceptionally high, yet the forward PE has compressed to a more modest level, hinting at earnings acceleration. A discounted cash‑flow analysis places intrinsic value well above the current price, suggesting a sizable upside potential. Recent operational news disclosed an almost 90% jump in adjusted EBITDA and an upward revision of full‑year sales and EBITDA guidance, underscoring strong top‑line momentum. The company generates solid operating and free cash flow, and its balance sheet shows ample cash despite a moderate debt load. With no dividend and a modest return on equity, the upside is primarily driven by growth expectations rather than income.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • price near support level
  • bearish MACD and decreasing volume
  • high short‑term volatility

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • upgraded sales and EBITDA guidance
  • strong EBITDA growth year‑over‑year
  • forward PE compression indicating earnings acceleration

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • DCF indicates significant undervaluation
  • growth trajectory in specialty chemicals
  • solid cash generation supporting balance‑sheet flexibility

Key Metrics & Analysis

Financial Health

Revenue Growth50.20%
Profit Margin-7.95%
P/E Ratio76.7
ROE3.17%
ROA3.68%
Debt/Equity75.89
P/B Ratio2.5
Op. Cash Flow$147.0M
Free Cash Flow$109.5M

Technical Analysis

TrendNeutral
RSI44.5
Support$12.51
Resistance$14.24
MA 20$13.21
MA 50$13.76
MA 200$10.89
MACDBearish
VolumeDecreasing
Fear & Greed Index92.27

Valuation

Fair Value$33.64
Target Price$16.20
Upside/Downside24.23%
GradeUndervalued
TypeBlend

Risk Assessment

Beta0.82
Volatility32.61%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.